

Table SII. Univariate and multiple logistic regressions performed for each disease (psoriasis, chronic spontaneous urticaria, and atopic dermatitis)

Possible predictors	Treatment of psoriasis with biologicals		Treatment of chronic spontaneous urticaria with biologicals		Treatment of atopic dermatitis with biologicals	
	Univariate analysis OR (95% CI)	Multivariate analysis n = 182 (93.3%) OR (95% CI)	Univariate analysis OR (95% CI)	Multivariate analysis n = 183 (93.8%) OR (95% CI)	Univariate analysis OR (95% CI)	Multivariate analysis n = 181 (92.8%) OR (95% CI)
Sex (male)	1.23 (0.70–2.17)	0.50 (0.23–1.06)	2.04 (1.15–3.62)	1.99 (1.03–3.84)	1.23 (0.70–2.17)	1.21 (0.61–2.40)
Number of patients with the respective disease	1.00 (1.00–1.00)	1.00 (1.00–1.00)	1.00 (1.00–1.00)	1.00 (1.00–1.00)	1.00 (1.00–1.00)	1.00 (1.00–1.00)
State (Lower Saxony)	1.08 (0.61–1.90)	0.88 (0.43–1.83)	1.26 (0.71–1.03)	1.63 (0.86–3.09)	1.99 (1.11–3.57)	2.13 (1.09–4.16)
Work experience	0.98 (0.94–1.01)	0.98 (0.94–1.02)	1.00 (0.97–1.03)	0.99 (0.96–1.03)	0.96 (0.93–1.00)	0.96 (0.92–1.00)
Physicians' concerns						
No experience with biologicals	0.13 (0.05–0.30)	0.11 (0.04–0.33)	0.22 (0.1–0.45)	0.23 (0.10–0.50)	0.20 (0.10–0.42)	0.19 (0.09–0.44)
Insufficient knowledge	0.24 (0.10–0.55)	–	0.26 (0.12–0.57)	–	0.21 (0.09–0.47)	–
Insecurity with guidelines	0.26 (0.11–0.64)	–	0.30 (0.13–0.96)	–	0.19 (0.08–0.48)	–
Lack of time for treatment adjustment	0.24 (0.12–0.50)	–	0.47 (0.25–0.91)	–	0.45 (0.23–0.86)	–
Complexity of medical pre-examination	0.21 (0.11–0.43)	0.30 (0.12–0.74)	0.49 (0.26–0.92)	–	0.42 (0.22–0.78)	–
Disapproval by colleagues	1.01 (0.39–2.61)	–	0.62 (0.24–1.61)	–	0.61 (0.23–1.58)	–
Disapproval by supervisor	0.17 (0.02–1.46)	–	0.34 (0.07–1.82)	–	0.31 (0.06–1.66)	–
Patients' concerns						
Patients' concerns with regard to side-effects	0.63 (0.35–1.11)	–	1.01 (0.75–1.78)	–	1.02 (0.58–1.80)	–
Patients' concerns for other reasons	0.55 (0.31–0.89)	–	0.96 (0.54–1.70)	–	0.93 (0.52–1.64)	–
External factors						
Insufficient reimbursement	0.37 (0.21–0.67)	–	0.85 (0.48–1.50)	–	0.82 (0.46–1.45)	–
Fear of regress	0.29 (0.16–0.54)	–	0.40 (0.22–0.71)	–	0.69 (0.30–1.21)	–
High costs	0.38 (0.22–0.69)	0.40 (0.20–0.81)	0.62 (0.35–1.09)	–	0.56 (0.32–1.00)	–
Previous regress claims	1.52 (0.51–4.57)	–	0.88 (0.30–2.60)	–	2.24 (0.68–7.40)	–
Concerns regarding biologicals themselves						
Concerns with regard to safety	0.26 (0.12–0.57)	–	0.47 (0.23–0.94)	–	0.39 (0.19–0.79)	–
Insufficient efficiency	0.45 (0.17–1.80)	–	0.09 (0.01–0.73)	–	0.09 (0.01–0.70)	–
Inappropriate risk benefit profile	0.41 (0.15–1.37)	–	0.22 (0.06–0.82)	–	0.13 (0.03–0.58)	–
Insufficient scientific evidence with regard to efficiency and quality	0.43 (0.08–2.28)	–	0.14 (0.02–1.18)	–	0.13 (0.02–1.13)	–
Sufficiency of conventional therapy	0.52 (0.28–0.96)	–	0.79 (0.44–1.54)	–	0.68 (0.37–1.24)	–

^a"Disapproval by supervisor" and "Previous regress claims" were not considered for calculating means of barrier strengths. The prescription of biologicals for the respective diseases (transformed by median split) was used as dependent variable. Significant factors in bold. The value "no barrier/does not apply" was used as reference. For multivariate analysis, backward selection with significance of $p=0.05$ was used.

CI: confidence interval; OR: odds ratio.